Cargando…

Glucagon-like peptide-1 mimetics, optimal for Asian type 2 diabetes patients with and without overweight/obesity: meta-analysis of randomized controlled trials

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are desirable for diabetes, especially in patients with overweight/obesity. We aimed to determine whether GLP-1RAs exhibit different glucose-lowering efficacies between Asian type 2 diabetes (T2D) patients with and without overweight/obesity. Rand...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Fang, Tang, Lizhi, Zhang, Yuwei, Lü, Qingguo, Tong, Nanwei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5700049/ https://www.ncbi.nlm.nih.gov/pubmed/29167470 http://dx.doi.org/10.1038/s41598-017-16018-9

Ejemplares similares

Impaired Secretion of Total Glucagon-like Peptide-1 in People with Impaired Fasting Glucose Combined Impaired Glucose Tolerance
por: Zhang, Fang, et al.
Publicado: (2012)

Efficacy of glucagon-like peptide-1 mimetics for neural regeneration
por: Sango, Kazunori, et al.
Publicado: (2015)

The effect of meal composition on postprandial glucagon-like peptide-1 response in overweight/obese participants
por: Franklin, Brian, et al.
Publicado: (2015)

Consideration of the diagnosis of hypertension accompanied with hypokalaemia: monism or dualism?
por: Lü, Qingguo, et al.
Publicado: (2018)

Glucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in Mice
por: Pocai, Alessandro, et al.
Publicado: (2009)

Glucagon-like peptide 1 in the pathophysiology and pharmacotherapy of clinical obesity
por: Anandhakrishnan, Ananthi, et al.
Publicado: (2016)

Glucagon-like Peptide-1 Receptor Analogues for the Treatment of Obesity
por: Williams, David M, et al.
Publicado: (2022)

Effects of glucagon-like peptide-1 receptor agonists on glucose excursion and inflammation in overweight or obese type 2 diabetic patients
por: Huang, Xiao-Min, et al.
Publicado: (2023)

Role of Glucagon‐Like Peptide‐1 Receptor Agonists in Achieving Weight Loss and Improving Cardiovascular Outcomes in People With Overweight and Obesity
por: Michos, Erin D., et al.
Publicado: (2023)

A Placebo-Controlled Study on the Effects of the Glucagon-Like Peptide-1 Mimetic, Exenatide, on Insulin Secretion, Body Composition and Adipokines in Obese, Client-Owned Cats
por: Hoelmkjaer, Kirsten M., et al.
Publicado: (2016)

Computational Peptide Design Cotargeting Glucagon and Glucagon-like Peptide-1 Receptors
por: Vishnoi, Shubham, et al.
Publicado: (2023)

Effects of Glucagon-Like-Peptide-1 Analogue Treatment in Genetic Obesity
por: Welling, Mila Sofie, et al.
Publicado: (2021)

Mycoprotein reduces energy intake and postprandial insulin release without altering glucagon-like peptide-1 and peptide tyrosine-tyrosine concentrations in healthy overweight and obese adults: a randomised-controlled trial
por: Bottin, Jeanne H., et al.
Publicado: (2016)

Stability of glucagon-like peptide 1 and glucagon in human plasma
por: Wewer Albrechtsen, Nicolai J, et al.
Publicado: (2015)

Glucagon-like peptide-1 and glucagon-like peptide-2 regulation during human liver regeneration
por: Ammann, Markus, et al.
Publicado: (2023)

The association of hypernatremia and hypertonic saline irrigation in hepatic hydatid cysts: A case report and retrospective study
por: Zeng, Rujun, et al.
Publicado: (2017)

Identical anthropometric characteristics of impaired fasting glucose combined with impaired glucose tolerance and newly diagnosed type 2 diabetes: anthropometric indicators to predict hyperglycaemia in a community-based prospective cohort study in southwest China
por: Zhang, Fang, et al.
Publicado: (2018)

Glucagon-Like Peptide-1 and Diabetes
por: Monami, Matteo
Publicado: (2011)

Clinical Impact of Glucagon-Like Peptide-1 Receptor Analogs on the Complications of Obesity
por: Yazıcı, Dilek, et al.
Publicado: (2022)

Crystal Structure of Glucagon-like Peptide-1 in Complex with the Extracellular Domain of the Glucagon-like Peptide-1 Receptor
por: Underwood, Christina Rye, et al.
Publicado: (2010)

Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
por: Lee, Seungah, et al.
Publicado: (2017)

Glucagon-like peptide 1 and Glucagon-like peptide 2 in relation to osteoporosis in non-diabetic postmenopausal women
por: Montes Castillo, María Cristina, et al.
Publicado: (2019)

Laminarin counteracts diet-induced obesity associated with glucagon-like peptide-1 secretion
por: Yang, Liusong, et al.
Publicado: (2017)

Coagonist of glucagon-like peptide-1 and glucagon receptors ameliorates kidney injury in murine models of obesity and diabetes mellitus
por: Patel, Vishal J, et al.
Publicado: (2018)

Regulation of intestinal lipid and lipoprotein metabolism by the proglucagon-derived peptides glucagon like peptide 1 and glucagon like peptide 2
por: Mulvihill, Erin E.
Publicado: (2018)

Pheochromocytoma crisis presenting with hypotension, hemoptysis, and abnormal liver function: A case report
por: Wu, Renhua, et al.
Publicado: (2018)

A Metabolomic Signature of Glucagon Action in Healthy Individuals With Overweight/Obesity
por: Vega, Rick B, et al.
Publicado: (2021)

Identification of key genes and pathways revealing the central regulatory mechanism of brain-derived glucagon-like peptide-1 on obesity using bioinformatics analysis
por: Shao, Yuwei, et al.
Publicado: (2022)

Usage of Glucagon-Like Peptide-1 for Obesity in Children; Updated Review of Clinicaltrials.gov
por: Alorfi, Nasser M, et al.
Publicado: (2023)

Glucagon-Like Peptide-1 Gene Therapy
por: Rowzee, Anne M., et al.
Publicado: (2011)

Glucagon-Like Peptide-1 and Diabetes 2012
por: Monami, Matteo, et al.
Publicado: (2012)

Glucagon-like peptide-1 analogues: An overview
por: Gupta, Vishal
Publicado: (2013)

Glucagon-like peptide 1 (GLP-1)
por: Müller, T.D., et al.
Publicado: (2019)

Optimization of a Glucagon-Like Peptide 1 Receptor Antagonist Antibody for Treatment of Hyperinsulinism
por: Peterson, Sean M., et al.
Publicado: (2023)

Glucagon and other proglucagon-derived peptides in the pathogenesis of obesity
por: Holst, Jens Juul
Publicado: (2022)

Reversal of Obesity and Insulin Resistance by a Non-Peptidic Glucagon-Like Peptide-1 Receptor Agonist in Diet-Induced Obese Mice
por: He, Min, et al.
Publicado: (2010)

Glucagon‐like peptide‐1 and cholecystokinin production and signaling in the pancreatic islet as an adaptive response to obesity
por: Linnemann, Amelia K, et al.
Publicado: (2016)

An impaired glucagon-like peptide-1 response is associated with prediabetes in polycystic ovary syndrome with obesity
por: Ferjan, Simona, et al.
Publicado: (2019)

Effects of glucagon‐like peptide‐1 analogue treatment in genetic obesity: A case series
por: Welling, Mila S., et al.
Publicado: (2021)

Hepatic stellate cells specific liposomes with the Toll‐like receptor 4 shRNA attenuates liver fibrosis
por: Zhang, Yuwei, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_k0abd25q6v2ei3g81a1te6dilu